A Cancer Research UK Phase I/IIa Trial of Chimpanzee Adenovirus Oxford 1 (ChAdOx1) and Modified Vaccinia Ankara (MVA) Vaccines Against MAGE-A3 and NY-ESO-1 With Standard of Care Treatment (Chemotherapy and an Immune Checkpoint Inhibitor)

Status: Suspended

Phase of Trial: Phase I/II

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VTP 600 (Primary) ; Antineoplastics; Programmed cell death 1 receptor modulators
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms MAGE

Most Recent Events

18 Mar 2025 Planned End Date changed from 1 Dec 2027 to 1 Oct 2026.
01 May 2024 Planned number of patients changed from 86 to 103.
01 May 2024 Planned End Date changed from 1 May 2025 to 1 Dec 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight